[go: up one dir, main page]

MA28685B1 - Derives de la quinazolinone, antagonistes de la vanilloide - Google Patents

Derives de la quinazolinone, antagonistes de la vanilloide

Info

Publication number
MA28685B1
MA28685B1 MA29565A MA29565A MA28685B1 MA 28685 B1 MA28685 B1 MA 28685B1 MA 29565 A MA29565 A MA 29565A MA 29565 A MA29565 A MA 29565A MA 28685 B1 MA28685 B1 MA 28685B1
Authority
MA
Morocco
Prior art keywords
vanilloid
antagonists
quinazolinone derivatives
salt form
quinazolinone
Prior art date
Application number
MA29565A
Other languages
English (en)
Inventor
Timothy John Ritchie
Andrew James Culshaw
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32696854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28685(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28685B1 publication Critical patent/MA28685B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cereal-Derived Products (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention porte sur l'utilisation d'un composé de la quinazolinone, de formule (I) dans laquelle: R1, R2, R3, R4, R5 et m sont tels que définis dans la spécification et dans les revendications, sous forme libre ou de sels et quand cela est possible sous forme de sels acidifiants, et s'utilisant en tant qu'antagonistes du vanilloïde.
MA29565A 2004-06-08 2006-12-28 Derives de la quinazolinone, antagonistes de la vanilloide MA28685B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0412769.2A GB0412769D0 (en) 2004-06-08 2004-06-08 Organic compounds

Publications (1)

Publication Number Publication Date
MA28685B1 true MA28685B1 (fr) 2007-06-01

Family

ID=32696854

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29565A MA28685B1 (fr) 2004-06-08 2006-12-28 Derives de la quinazolinone, antagonistes de la vanilloide

Country Status (29)

Country Link
US (4) US7960399B2 (fr)
EP (1) EP1755606B2 (fr)
JP (2) JP4703650B2 (fr)
KR (2) KR20100101017A (fr)
CN (1) CN1956721B (fr)
AT (1) ATE376833T1 (fr)
AU (2) AU2005251476C1 (fr)
BR (1) BRPI0511933B8 (fr)
CA (1) CA2567821C (fr)
CY (1) CY1107846T1 (fr)
DE (1) DE602005003128T3 (fr)
DK (1) DK1755606T4 (fr)
EC (2) ECSP067067A (fr)
ES (1) ES2293584T5 (fr)
GB (1) GB0412769D0 (fr)
HR (1) HRP20070577T4 (fr)
IL (1) IL179532A (fr)
MA (1) MA28685B1 (fr)
MX (1) MXPA06014249A (fr)
NO (1) NO338181B1 (fr)
NZ (1) NZ551630A (fr)
PL (1) PL1755606T5 (fr)
PT (1) PT1755606E (fr)
RU (2) RU2449995C2 (fr)
SG (1) SG153811A1 (fr)
SI (1) SI1755606T2 (fr)
TN (1) TNSN06405A1 (fr)
WO (1) WO2005120510A1 (fr)
ZA (1) ZA200609634B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
ES2399928T3 (es) 2006-08-23 2013-04-04 Neurogen Corporation Análogos de 2-fenoxipirimidinona
CN101558069A (zh) * 2006-11-06 2009-10-14 神经能质公司 顺式环己基取代的嘧啶酮衍生物
WO2009010529A1 (fr) * 2007-07-18 2009-01-22 Novartis Ag Combinaisons synergiques d'antagonistes vr-1 et d'inhibiteurs de cox-2
US8915362B2 (en) 2008-10-08 2014-12-23 Ultimed, Inc. Sharps container
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US9776975B2 (en) 2013-03-05 2017-10-03 University Of Notre Dame Du Lac Quinazolinone antibiotics
US10016425B2 (en) 2016-11-03 2018-07-10 King Saud University Anti-ulcerative colitis compound
CR20210215A (es) 2018-10-31 2021-06-17 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
CN113453686B (zh) * 2019-02-15 2025-04-15 博士伦爱尔兰有限公司 治疗眼表痛的方法
EP4431497A1 (fr) 2019-02-15 2024-09-18 Bausch + Lomb Ireland Limited Formes cristallines de 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile et leurs formulations
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
WO2022029656A1 (fr) 2020-08-06 2022-02-10 Novartis Ag Formes cristallines de 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile et formulations correspondantes
CN116456986A (zh) * 2020-11-17 2023-07-18 苏州晶云药物科技股份有限公司 一种喹唑啉酮衍生物的新晶型及其制备方法
UY39681A (es) 2021-03-26 2022-10-31 Novartis Ag Derivados de ciclobutilo 1,3–sustituidos y sus usos
JP2025531367A (ja) 2022-09-21 2025-09-19 ボシュ ＋ ロム アイルランド リミテッド Ｔｒｐｖ１アンタゴニストの結晶多形形態およびその製剤
KR20250030194A (ko) 2023-08-24 2025-03-05 코웨이 주식회사 출수 장치

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US95650A (en) * 1869-10-12 Improvement in machines for bending sheet-metal for cornices
US220227A (en) * 1879-10-07 Improvement in stri klng-movements for clocks
US49728A (en) * 1865-09-05 Improvement
US82365A (en) * 1868-09-22 thompson
DE239090C (fr) 1906-11-01
US2749344A (en) 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
DE1224316B (de) 1961-03-18 1966-09-08 Beiersdorf & Co Ag P Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen
DE1232152B (de) * 1962-06-27 1967-01-12 Heyden Chem Fab Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten
US3515787A (en) * 1962-06-27 1970-06-02 Squibb & Sons Inc Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones
GB1003802A (en) * 1963-06-04 1965-09-08 Searle & Co Pyrimidinone derivatives
DE1280874B (de) * 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US3317388A (en) 1964-11-20 1967-05-02 Wallace & Tiernan Inc Methods for treating pain
US3864362A (en) 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
BE793594A (fr) 1972-01-03 1973-07-02 Pfizer Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants
GB1495305A (en) 1975-09-12 1977-12-14 Pfizer Ltd 3-phenyl-4-oxo-4h-benzopyran derivatives
US4501755A (en) 1981-05-01 1985-02-26 Pennwalt Corporation Isoflavones useful as anti-inflammatory agents
JPS59128376A (ja) * 1983-01-13 1984-07-24 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
SU1262927A1 (ru) 1985-01-09 1997-11-20 Институт физико-органической химии и углехимии АН УССР Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина
JPS62201882A (ja) 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
JPS62193605A (ja) * 1986-02-20 1987-08-25 Toray Ind Inc 半透性複合膜の製造方法
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
WO1992013535A1 (fr) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5284853A (en) 1993-04-23 1994-02-08 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5294617A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0635263A3 (fr) 1993-06-28 1995-09-27 American Cyanamid Co Antagonistes de l'angiotensine II (AII) comme inhibiteurs de la croissance du tissu adipeux.
HUT68558A (en) 1993-07-20 1995-06-28 Chinoin Gyogyszer Es Vegyeszet Method for preparing isoflavon derivatives
IL112235A (en) 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
JPH07258224A (ja) 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd 二環性化合物
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
CA2214131C (fr) * 1995-03-14 2009-06-23 Novartis Ag Derives de phenyle a trisubstitution
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997028118A1 (fr) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Procede de preparation d'acides anthreniliques
EP0920319A4 (fr) 1996-05-20 2002-05-02 Merck & Co Inc Antagonistes de la gonadoliberine
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
IT1289154B1 (it) 1997-01-03 1998-09-29 Chiesi Farma Spa Derivati di isoflavone loro preparazione e loro impiego terapeutico
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
DE69819345T2 (de) 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
AU2466799A (en) 1998-01-22 1999-08-09 Regents Of The University Of California, The Nucleic acid sequences encoding capsaicin receptors
CN1310706A (zh) 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE60024785T2 (de) * 1999-02-22 2006-09-14 Amorepacific Corp. Vanilloid-analoge die resiniferatoxin-pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
AU4742101A (en) 2000-03-17 2001-10-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
CA2417507A1 (fr) * 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci
FR2815033B1 (fr) 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP4205430B2 (ja) 2001-03-26 2009-01-07 ノバルティス アクチエンゲゼルシャフト 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体
AU2002325381A1 (en) 2001-07-31 2003-02-24 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
AU2003238157A1 (en) † 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
CN1665791A (zh) 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
EP1398032A1 (fr) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-oxoquinazolines se liant au récepteur nucléair LXR
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
US20060052345A1 (en) 2002-11-04 2006-03-09 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
EP1611112B1 (fr) 2003-02-11 2012-08-22 Vernalis (Cambridge) Limited Composes d'isoxazole utiles comme inhibiteurs des proteines de choc thermique
US20060089353A1 (en) 2003-03-06 2006-04-27 Maki Iwahashi Indole derivative compounds and drugs containing the compounds as the active ingredient
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005040112A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes a activite antagoniste de pgd2
AU2004290626A1 (en) 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
BRPI0507629A (pt) 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CA2607929A1 (fr) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited Pyrimidine-4(3h)-ones bicycliques fusionnees substituees en 2,3 modulant la fonction du recepteur vanilloide-1 (vr1)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2009010529A1 (fr) 2007-07-18 2009-01-22 Novartis Ag Combinaisons synergiques d'antagonistes vr-1 et d'inhibiteurs de cox-2
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists

Also Published As

Publication number Publication date
WO2005120510A1 (fr) 2005-12-22
SI1755606T2 (sl) 2011-10-28
CN1956721B (zh) 2015-05-13
HRP20070577T3 (hr) 2008-08-31
RU2449995C2 (ru) 2012-05-10
JP2011105738A (ja) 2011-06-02
ATE376833T1 (de) 2007-11-15
AU2005251476B2 (en) 2009-12-03
US8809528B2 (en) 2014-08-19
SI1755606T1 (sl) 2008-08-31
KR101018607B1 (ko) 2011-03-04
JP5400812B2 (ja) 2014-01-29
BRPI0511933A (pt) 2008-01-22
RU2006146632A (ru) 2008-07-20
JP2008501763A (ja) 2008-01-24
US8211902B2 (en) 2012-07-03
IL179532A (en) 2012-12-31
US20080194595A1 (en) 2008-08-14
PL1755606T3 (pl) 2008-03-31
SG153811A1 (en) 2009-07-29
ECSP12007067A (es) 2012-03-30
KR20070021244A (ko) 2007-02-22
DK1755606T4 (da) 2011-10-24
HRP20070577T4 (hr) 2011-10-31
ECSP067067A (es) 2007-01-26
HK1105577A1 (en) 2008-02-22
NZ551630A (en) 2010-08-27
JP4703650B2 (ja) 2011-06-15
NO20070122L (no) 2007-03-01
RU2396261C2 (ru) 2010-08-10
ZA200609634B (en) 2008-08-27
CN1956721A (zh) 2007-05-02
KR20100101017A (ko) 2010-09-15
AU2005251476C1 (en) 2011-09-15
GB0412769D0 (en) 2004-07-07
ES2293584T5 (es) 2011-11-23
DE602005003128D1 (de) 2007-12-13
CA2567821A1 (fr) 2005-12-22
TNSN06405A1 (en) 2008-02-22
DE602005003128T3 (de) 2012-02-09
BRPI0511933B1 (pt) 2019-04-24
BRPI0511933B8 (pt) 2021-05-25
ES2293584T3 (es) 2008-03-16
US9102653B2 (en) 2015-08-11
US20140315932A1 (en) 2014-10-23
CA2567821C (fr) 2013-12-24
MXPA06014249A (es) 2007-02-19
EP1755606A1 (fr) 2007-02-28
US20120184571A1 (en) 2012-07-19
DK1755606T3 (da) 2008-03-03
US7960399B2 (en) 2011-06-14
EP1755606B2 (fr) 2011-06-29
PL1755606T5 (pl) 2011-11-30
CY1107846T1 (el) 2013-06-19
RU2010112450A (ru) 2011-10-10
EP1755606B1 (fr) 2007-10-31
NO338181B1 (no) 2016-08-01
DE602005003128T2 (de) 2008-08-07
PT1755606E (pt) 2008-01-21
IL179532A0 (en) 2007-05-15
AU2005251476A1 (en) 2005-12-22
AU2009233684A1 (en) 2009-11-26
US20110195983A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
ECSP12007067A (es) Derivados de quinazolinona útiles como antagonistas vanilloides
EA200870116A1 (ru) Бициклические гетероарильные соединения
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2007047646A3 (fr) Dihydroisoindolones substituées pouvant être employées dans le traitement de troubles des kinases
WO2006017054A3 (fr) Composes heteroaryles tricycliques utiles en tant qu'inhibiteurs de kinase
ATE445593T1 (de) Acetylenderivate
UY29040A1 (es) Procedimiento de amino-tropano, su preparación y aplicación en terapéutica
CR9578A (es) Inhibidores de la adenilato ciclasa soluble
ECSP088170A (es) Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano, su preparación y su aplicación en terapéutica
MX2007001952A (es) Compuestos y composiciones utiles como inhibidores de catepsina-s.
ATE455095T1 (de) Vanilloidrezeptor trpv1-antagonisten
NO20060603L (no) Fremgangsmate for fremstillingen av fenyltetrazolderivater
TW200745053A (en) 9-Aminocarbonylsubstituted derivatives of glycylcyclines
EA200870045A1 (ru) СУЛЬФОКСИМИННЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ p38 MAP КИНАЗЫ
DE602005024828D1 (de) Rezeptors wirken
ATE417040T1 (de) Nitratester von phenylaminothiophen- essigsäurederivaten